Parallel studies have also confirmed that MMP14 [30] and ITGB1 [31] are upregulated in hepatic fibrosis, which is gradually reduced with recovery suggesting that their blocking could be a potential anti-inflammatory therapeutic strategy in NASH. This evidence concerns the gene ITGB1 and metabolic dysfunction-associated steatohepatitis.